Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: A multicenter prospective study

Do Young Kim, Beom Jin Park, Yun Hwan Kim, Kwang Hyub Han, Sung Bum Cho, Kyu Ran Cho, Sun Ho Uhm, Jae Gol Choe, Jong Young Choi, Ho Jong Chun, Han Chu Lee, Dong Il Gwon, Kwang Hun Lee, Jung Hwan Yoon, Jin Wook Chung, Chang Won Kim, Jeong Heo, Jae Kyu Kim, Young Eun Joo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: The aim of this prospective study was to reveal the efficacy and safety of Yttrium-90 (90Y) radioembolization in Korean patients with hepatocellular carcinoma (HCC). Methods: A total of 40 HCC patients were prospectively recruited from 7 centers. The response to treatment was assessed on the basis of the modified Response Evaluation Criteria in Solid Tumors criteria. The time to progression and overall survival were also evaluated, and the assessment of safety was done according to National Cancer Institute Common Terminology Criteria, Version 3.0. Results: Forty-two treatments of 90Y radioembolization were carried out. Median follow-up was 29 months. At 3 months, the complete response, partial response (PR), and stable disease were seen in 4 (10.0%), 19 (47.5%), and 15 (37.5%) patients, respectively. The response rate was 57.5% (23/40), and disease control rate was 95% (38/40) at 3 months. The response rate at 6 months was 63.9% (23/36), and disease control rate was 83.3% (30/36). The median time to progression was 18 months. During follow-up, 10 HCC-related deaths occurred and the 3-year survival rate was 75%. In 19 patients with Barcelona Clinic Liver Cancer-B stage, the 3-year survival rate was 50%. The tumor number (> 5) was the only significant predictor associated with survival. The most common adverse event was abdominal pain of mild to moderate degree, and all the complications were manageable. Twenty-six (65%) patients underwent other treatments such as transarterial chemoembolization because of local progression or remnant viable lesion. Conclusions: 90Y radioembolization might be a safe and effective treatment modality in intermediate-stage to advanced-stage HCC.

Original languageEnglish
Pages (from-to)495-501
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume38
Issue number5
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Yttrium
Microspheres
Multicenter Studies
Hepatocellular Carcinoma
Prospective Studies
Survival Rate
Safety
Survival
National Cancer Institute (U.S.)
Therapeutics
Liver Neoplasms
Terminology
Abdominal Pain
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Do Young ; Park, Beom Jin ; Kim, Yun Hwan ; Han, Kwang Hyub ; Cho, Sung Bum ; Cho, Kyu Ran ; Uhm, Sun Ho ; Choe, Jae Gol ; Choi, Jong Young ; Chun, Ho Jong ; Lee, Han Chu ; Gwon, Dong Il ; Lee, Kwang Hun ; Yoon, Jung Hwan ; Chung, Jin Wook ; Kim, Chang Won ; Heo, Jeong ; Kim, Jae Kyu ; Joo, Young Eun. / Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma : A multicenter prospective study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2015 ; Vol. 38, No. 5. pp. 495-501.
@article{81f067947b9c4422a4b3f1e1cdbc3c29,
title = "Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: A multicenter prospective study",
abstract = "Objectives: The aim of this prospective study was to reveal the efficacy and safety of Yttrium-90 (90Y) radioembolization in Korean patients with hepatocellular carcinoma (HCC). Methods: A total of 40 HCC patients were prospectively recruited from 7 centers. The response to treatment was assessed on the basis of the modified Response Evaluation Criteria in Solid Tumors criteria. The time to progression and overall survival were also evaluated, and the assessment of safety was done according to National Cancer Institute Common Terminology Criteria, Version 3.0. Results: Forty-two treatments of 90Y radioembolization were carried out. Median follow-up was 29 months. At 3 months, the complete response, partial response (PR), and stable disease were seen in 4 (10.0{\%}), 19 (47.5{\%}), and 15 (37.5{\%}) patients, respectively. The response rate was 57.5{\%} (23/40), and disease control rate was 95{\%} (38/40) at 3 months. The response rate at 6 months was 63.9{\%} (23/36), and disease control rate was 83.3{\%} (30/36). The median time to progression was 18 months. During follow-up, 10 HCC-related deaths occurred and the 3-year survival rate was 75{\%}. In 19 patients with Barcelona Clinic Liver Cancer-B stage, the 3-year survival rate was 50{\%}. The tumor number (> 5) was the only significant predictor associated with survival. The most common adverse event was abdominal pain of mild to moderate degree, and all the complications were manageable. Twenty-six (65{\%}) patients underwent other treatments such as transarterial chemoembolization because of local progression or remnant viable lesion. Conclusions: 90Y radioembolization might be a safe and effective treatment modality in intermediate-stage to advanced-stage HCC.",
author = "Kim, {Do Young} and Park, {Beom Jin} and Kim, {Yun Hwan} and Han, {Kwang Hyub} and Cho, {Sung Bum} and Cho, {Kyu Ran} and Uhm, {Sun Ho} and Choe, {Jae Gol} and Choi, {Jong Young} and Chun, {Ho Jong} and Lee, {Han Chu} and Gwon, {Dong Il} and Lee, {Kwang Hun} and Yoon, {Jung Hwan} and Chung, {Jin Wook} and Kim, {Chang Won} and Jeong Heo and Kim, {Jae Kyu} and Joo, {Young Eun}",
year = "2015",
month = "10",
day = "1",
doi = "10.1097/COC.0b013e3182a78dba",
language = "English",
volume = "38",
pages = "495--501",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

Kim, DY, Park, BJ, Kim, YH, Han, KH, Cho, SB, Cho, KR, Uhm, SH, Choe, JG, Choi, JY, Chun, HJ, Lee, HC, Gwon, DI, Lee, KH, Yoon, JH, Chung, JW, Kim, CW, Heo, J, Kim, JK & Joo, YE 2015, 'Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma: A multicenter prospective study', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 38, no. 5, pp. 495-501. https://doi.org/10.1097/COC.0b013e3182a78dba

Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma : A multicenter prospective study. / Kim, Do Young; Park, Beom Jin; Kim, Yun Hwan; Han, Kwang Hyub; Cho, Sung Bum; Cho, Kyu Ran; Uhm, Sun Ho; Choe, Jae Gol; Choi, Jong Young; Chun, Ho Jong; Lee, Han Chu; Gwon, Dong Il; Lee, Kwang Hun; Yoon, Jung Hwan; Chung, Jin Wook; Kim, Chang Won; Heo, Jeong; Kim, Jae Kyu; Joo, Young Eun.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 38, No. 5, 01.10.2015, p. 495-501.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Radioembolization with Yttrium-90 resin microspheres in hepatocellular carcinoma

T2 - A multicenter prospective study

AU - Kim, Do Young

AU - Park, Beom Jin

AU - Kim, Yun Hwan

AU - Han, Kwang Hyub

AU - Cho, Sung Bum

AU - Cho, Kyu Ran

AU - Uhm, Sun Ho

AU - Choe, Jae Gol

AU - Choi, Jong Young

AU - Chun, Ho Jong

AU - Lee, Han Chu

AU - Gwon, Dong Il

AU - Lee, Kwang Hun

AU - Yoon, Jung Hwan

AU - Chung, Jin Wook

AU - Kim, Chang Won

AU - Heo, Jeong

AU - Kim, Jae Kyu

AU - Joo, Young Eun

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objectives: The aim of this prospective study was to reveal the efficacy and safety of Yttrium-90 (90Y) radioembolization in Korean patients with hepatocellular carcinoma (HCC). Methods: A total of 40 HCC patients were prospectively recruited from 7 centers. The response to treatment was assessed on the basis of the modified Response Evaluation Criteria in Solid Tumors criteria. The time to progression and overall survival were also evaluated, and the assessment of safety was done according to National Cancer Institute Common Terminology Criteria, Version 3.0. Results: Forty-two treatments of 90Y radioembolization were carried out. Median follow-up was 29 months. At 3 months, the complete response, partial response (PR), and stable disease were seen in 4 (10.0%), 19 (47.5%), and 15 (37.5%) patients, respectively. The response rate was 57.5% (23/40), and disease control rate was 95% (38/40) at 3 months. The response rate at 6 months was 63.9% (23/36), and disease control rate was 83.3% (30/36). The median time to progression was 18 months. During follow-up, 10 HCC-related deaths occurred and the 3-year survival rate was 75%. In 19 patients with Barcelona Clinic Liver Cancer-B stage, the 3-year survival rate was 50%. The tumor number (> 5) was the only significant predictor associated with survival. The most common adverse event was abdominal pain of mild to moderate degree, and all the complications were manageable. Twenty-six (65%) patients underwent other treatments such as transarterial chemoembolization because of local progression or remnant viable lesion. Conclusions: 90Y radioembolization might be a safe and effective treatment modality in intermediate-stage to advanced-stage HCC.

AB - Objectives: The aim of this prospective study was to reveal the efficacy and safety of Yttrium-90 (90Y) radioembolization in Korean patients with hepatocellular carcinoma (HCC). Methods: A total of 40 HCC patients were prospectively recruited from 7 centers. The response to treatment was assessed on the basis of the modified Response Evaluation Criteria in Solid Tumors criteria. The time to progression and overall survival were also evaluated, and the assessment of safety was done according to National Cancer Institute Common Terminology Criteria, Version 3.0. Results: Forty-two treatments of 90Y radioembolization were carried out. Median follow-up was 29 months. At 3 months, the complete response, partial response (PR), and stable disease were seen in 4 (10.0%), 19 (47.5%), and 15 (37.5%) patients, respectively. The response rate was 57.5% (23/40), and disease control rate was 95% (38/40) at 3 months. The response rate at 6 months was 63.9% (23/36), and disease control rate was 83.3% (30/36). The median time to progression was 18 months. During follow-up, 10 HCC-related deaths occurred and the 3-year survival rate was 75%. In 19 patients with Barcelona Clinic Liver Cancer-B stage, the 3-year survival rate was 50%. The tumor number (> 5) was the only significant predictor associated with survival. The most common adverse event was abdominal pain of mild to moderate degree, and all the complications were manageable. Twenty-six (65%) patients underwent other treatments such as transarterial chemoembolization because of local progression or remnant viable lesion. Conclusions: 90Y radioembolization might be a safe and effective treatment modality in intermediate-stage to advanced-stage HCC.

UR - http://www.scopus.com/inward/record.url?scp=84941881298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941881298&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182a78dba

DO - 10.1097/COC.0b013e3182a78dba

M3 - Article

C2 - 24064753

AN - SCOPUS:84941881298

VL - 38

SP - 495

EP - 501

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -